Covered recipient · General Payments record
KYLE RAJ BHATIA
Allopathic & Osteopathic Physicians Dermatology
General Payments · PY2021–2024
$1,606.65
- Reported across 35 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $701.75 | 15 |
| Education | $99.00 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| MIMEDX Group, Inc. | $157.12 | 1 |
| Janssen Biotech, Inc. | $131.72 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $124.47 | 1 |
| ABBVIE INC. | $93.89 | 4 |
| PFIZER INC. | $84.35 | 1 |
| GENZYME CORPORATION | $71.61 | 2 |
| UCB, Inc. | $36.48 | 1 |
| Regeneron Healthcare Solutions, Inc. | $34.53 | 1 |
| Galderma Laboratories, L.P. | $28.55 | 1 |
| LEO Pharma Inc. | $19.72 | 1 |
| Lilly USA, LLC | $18.31 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $25.05 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103321970 | CMS |
| ABBVIE INC. | $24.51 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103321972 | CMS |
| ABBVIE INC. | $18.12 | 11/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103321974 | CMS |
| ABBVIE INC. | $26.21 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103321976 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $124.47 | 06/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118246303 | CMS |
| Galderma Laboratories, L.P. | $28.55 | 09/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145286481 | CMS |
| GENZYME CORPORATION | $43.72 | 12/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139752759 | CMS |
| GENZYME CORPORATION | $27.89 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139752761 | CMS |
| Janssen Biotech, Inc. | $32.72 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078591933 | CMS |
| Janssen Biotech, Inc. | $99.00 | 12/27/2024 | Education | Undisputed | 01/23/2026 | 1078591994 | CMS |
| LEO Pharma Inc. | $19.72 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152620381 | CMS |
| Lilly USA, LLC | $18.31 | 02/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135129386 | CMS |
| MIMEDX Group, Inc. | $157.12 | 03/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140255393 | CMS |
| PFIZER INC. | $84.35 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131568721 | CMS |
| Regeneron Healthcare Solutions, Inc. | $34.53 | 10/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114009993 | CMS |
| UCB, Inc. | $36.48 | 09/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143019093 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.